Computational approaches for drug repositioning and combination therapy design

Journal of Bioinformatics and Computational Biology

Volumn 8, Issue 3, 2010, Pages 593-606

  Kotelnikova, Ekaterina ^a,b   Yuryev, Anton ^a   Mazo, Ilya ^a   Daraselia, Nikolai ^a  

^a Ariadne Genomics Inc   (United States)

^b STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

Author keywords

Angiogenesis; Drug repositioning; Enrichment analysis; Glioblastoma; MedScan; Systems biology

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; COMBINATORIAL CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG EFFECT; GLIOBLASTOMA; HUMAN; METABOLISM; METHODOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; DRUG DESIGN; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 77953682031     PISSN: 02197200     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0219720010004732     Document Type: Conference Paper

References (30)

1. Rothstein JD et al., Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression, Nature 433:73-77, 2005.
2. Kruger EA, Figg WD, TNP-470: An angiogenesis inhibitor in clinical development for cancer, Expert Opin Investig Drugs 9:1383-1396, 2000.
3. Guerin PJ et al., Malaria: Current status of control, diagnosis, treatment, and a proposed agenda for research and development, Lancet Infect Dis 2:564-573, 2002.
4. Fang J et al., Treatment of acute promyelocytic leukemia with ATRA and As2O3: A model of molecular target-based cancer therapy, Cancer Biol Ther 1:614-620, 2002.
5. Chong CR, Sullivan DJ, New uses for old drugs, Nature 448(7154):645-646, 2007.
6. Yuryev A, Mulyukov Z, Kotelnikova E, Maslov S, Egorov S, Nikitin A et al., Automatic pathway building in biological association networks, BMC Bioinformatics 7:171, 2006.
7. Nikitin A, Egorov S, Daraselia N, Mazo I, Pathway studio - the analysis and navigation of molecular networks, Bioinformatics 19(16):2155-2157, 2003.
8. Yuryev A, Kotelnikova E, Daraselia N, Ariadne's chemEffect and pathway studio knowledge base, Expert Opinion on Drug Discovery 4(12):1307-1318, 2009.
9. Daraselia N, Yuryev A, Egorov S, Novichkova S, Nikitin A, Mazo I, Extracting human protein interactions from MEDLINE using a full-sentence parser, Bioinformatics 20(5):604-611, 2004.
10. Sivachenko A, Yuryev A, Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism, Expert Opinion on Therapeutic Targets 11(3):411-421, 2007.
11. Sivachenko AY, Yuryev A, Daraselia N, Mazo I, Molecular networks in microarray analysis, J Bioinform Comput Biol 5(2B):429-456, 2007.
12. Yen ML, Su JL, Chien CL, Tseng KW, Yang CY, Chen WF, Chang CC, Kuo ML, Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts, Mol Pharmacol 68(4):1061-1073, 2005.
13. Bunone G, Briand PA, Miksicek RJ, Picard D, Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBO J 15:2174-2183, 1996.
14. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Saski H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P, Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science 270:1491-1494, 1995.
15. Wang R, Zhang QG, Han D, Xu J, Lü Q, Zhang GY, Inhibition of MLK3-MKK4/7- JNK1/2 pathway by Akt1 in exogenous estrogen-induced neuroprotection against transient global cerebral ischemia by a non-genomic mechanism in male rats, J Neurochem 99(6):1543-1554, 2006.
16. Wong ML, Kaye AH, Hovens CM, Targeting malignant glioma survival signalling to improve clinical outcomes, J Clin Neurosci 21:301-308, 2007.
17. Tuettenberg J, Friedel C, Vajkoczy P, Angiogenesis in malignant glioma - a target for antitumor therapy?, Crit Rev Oncol Hematol 59(3):181-193, 2006.
18. Ziegler DS, et al., Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins, J Clin Invest 118(9):3109-3122, 2008.
19. Ohgaki H, Kleihues P, Genetic pathways to primary and secondary glioblastoma, Am J Pathol 170(5):1445-1453, 2007.
20. Ohgaki H, Genetic pathways to glioblastomas, Neuropathology 25(1):1-7, 2005.
21. Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, et al., Downregulation of RUNX3 and TES by hypermethylation in glioblastoma, Oncogene 26(4):583-593, 2007.
22. Cheadle C et al., Analysis of microarray data using Z score transformation, The Journal of Molecular Diagnostics JMD 5(2):73-81, 2003.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci USA 102(43):15545-15550, 2005.
24. Xie D, Yin D, Tong X et al., Cyr61 is overexpressed in gliomas and involved in integrinlinked kinase-mediated Akt and -catenin-TCF/Lef signaling pathways, Cancer Res 64:1987-1996, 2004.
25. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF, Cyr61, a product of a growth factorinducible immediate early gene, promotes angiogenesis and tumor growth, Proc Natl Acad Sci USA 95:6355-6360, 1998.
26. Jin Y, Kim HP, Ifedigbo E, Lau LF, Choi AM, Cyr61 protects against hyperoxiainduced cell death via Akt pathway in pulmonary epithelial cells, Am J Respir Cell Mol Biol 33(3):297-302, 2005.
27. Kunz M, Moeller S, Koczan D, Lorenz P, Wenger RH, Glocker MO, Thiesen HJ, Gross G, Ibrahim SM, Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells, J Biol Chem 278(46):45651-115660, 2003.
28. Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R, Expression and regulation of Cyr61 in human breast cancer cell lines, Oncogene 21(6):964-973, 2002.
29. Vergote I, Abram P, Fulvestrant, a new treatment option for advanced breast cancer: Tolerability versus existing agents, Ann Oncol 17(2):200-204, 2006.
30. Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, Paulus W, Glioblastoma cells release factors that disrupt blood-brain barrier features, Acta Neuropathol 107(3):272-276, 2004.